pharmaphorum

Lilly points to long-lasting weight loss with orforglipron

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...
pharmaphorum

As year-end nears, pharma groups plump up their pipelines

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...
pharmaphorum

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
pharmaphorumOpinion

Europe has the tools to fight superbugs. Let’s use them.

The ECDC warns of a ‘perfect storm’ and calls for innovation, including through the development of new medicines, enhanced ...
pharmaphorum

Takeda plans filings for Sotyktu rival on new psoriasis data

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
pharmaphorum

MSD claims two national priority vouchers; report

According to Reuters, MSD – known as Merck & Co in the US and Canada – is set to be the recipient of the 17th and 18th ...
pharmaphorumOpinion

Six ways the NHS can become the UK’s greatest testbed for technology innovation

The UK has reached a critical inflection point in its digital journey. Over $40 billion in fresh commitments from global ...
pharmaphorum

On the future of AI in life sciences, with women at the helm

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...
pharmaphorum

FDA’s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...